ERBB2 and neoplasm: Meanwhile, the efficacy of olaparib was assessed in a germline breast cancer susceptibility gene 1/2 (BRCA1/2)-mutated HER2-negative population stratified by HR status and receipt of neoadjuvant therapy, using different combinations of factors such as nodal status, tumour size, pathologic complete response (pCR) and CPS + EG score [16].